Shaymaa GlhoomAya FerganyDina El‑ArabyAsmaa A. AbdelkhalekAsmaa GomaaEman O. ZayedMohamed Abd‑ElGwad2024-11-172024-11-172024-12-01Glhoom, S., Fergany, A., El-Araby, D., Abdelkhalek, A. A., Gomaa, A., Zayed, E. O., & Abd-ElGwad, M. (2024). The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis. European Journal of Medical Research, 29(1). https://doi.org/10.1186/s40001-023-01549-xhttps://doi.org/10.1186/s40001-023-01549-xhttps://repository.msa.edu.eg/handle/123456789/6239Background During the COVID-19 pandemic, some populations, including immunocompromised patients, could not tolerate COVID-19 vaccination or had low responses. Evusheld is a combined neutralizing monoclonal antibody containing tixagevimab and cilgavimab. The World Health Organization (WHO) has approved this combination as preexposure prophylaxis (PrEP) and treatment for immunocompromised patients. With the new variant, the (WHO) recommended an increase in dose from 300 to 600 mg with a booster dose after 6 months. The target of this review was to compare the efcacy of the two doses, 300 mg and 600 mg of tixagevimab/cilgavimab (Evusheld) as prophy‑ laxis for higher-risk individuals to reveal if there is a signifcant diference in efcacy between those two doses of the drug.en-USCilgavimabTixagevimabEvusheldAZD7442COVID-19Articlehttps://doi.org/10.1186/s40001-023-01549-x